As of May 7, 2026, 09:37, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) surged by 2.46%. Component stocks such as LEPU BIO-B rose by 6.23%, 3SBIO increased by 5.44%, BeiGene climbed by 5.11%, and other stocks like Rongchang Bio and Kintor Pharmaceutical also followed suit. The Hong Kong Stock Connect Innovative Drug ETF Bosera (520690) rose by 2.13%, with the latest price reported at 0.81 yuan.

In terms of liquidity, the Hong Kong Stock Connect Innovative Drug ETF Bosera had a turnover of 3.24% during the day, with a transaction volume of 14.9231 million yuan. Looking at a longer time frame, as of May 6, the average daily transaction volume of the Hong Kong Stock Connect Innovative Drug ETF Bosera over the past week was 165 million yuan.

Recently, the pharmaceutical and biotechnology industry has shown signs of a rebound from the bottom, with revenue and net profit attributable to shareholders in the first quarter of 2026 increasing by 2.0% and 5.0% year-on-year, respectively. The growth rate of net profit excluding non-recurring items reached 6.0%, significantly better than the negative growth performance for the entire year of 2025. Among them, innovative drugs (Bio-Pharma) and the CXO sector have become core drivers, with revenue growth rates in Q1 2026 ranking first and second among sub-sectors; representative companies such as Innovent Biologics, Haisco Pharmaceutical, and Zai Lab saw product revenue growth exceeding 75%, with the first drug holding reaching 1300%, confirming the acceleration of commercialization and the value of business development overseas. The industry is transitioning from "Made in China" to "Created in China," and globalization is still in its early stages, with a clear logic for high growth.

According to a research report from Guojin Securities, under the accumulation of multiple favorable factors, the innovative drug sector is entering a triple cycle of performance, valuation, and events. It is recommended to focus on leading targets, biotech companies turning losses into profits, and academic conference catalysts such as ASCO to seize long-term growth opportunities in innovative drugs. 1) From the perspective of fundamental improvement, pay attention to innovative drug companies that are expected to turn profitable in the historic milestone from 2025 to 2026; 2) From the perspective of clinical data catalysts, focus on key clinical data disclosures for potential PD-1/VEGF dual antibodies, ADCs, small nucleic acids, TCE, and other key track varieties, as this data is expected to further become catalysts for valuation recovery.

In terms of capital inflow, the latest net inflow for the Hong Kong Stock Connect Innovative Drug ETF Bosera was 18.2832 million yuan. Over a longer time frame, there were net inflows on 5 out of the last 7 trading days, totaling 46.4001 million yuan, with an average daily net inflow of 6.6286 million yuan.

The Hong Kong Stock Connect Innovative Drug ETF Bosera closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which aims to reflect the performance of Hong Kong-listed companies that can be traded through the Hong Kong Stock Connect and are related to the research, development, and production of innovative drugs.

Data shows that as of May 6, 2026, the top ten weighted stocks in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index (HSSCPB) are Kangfang Biologics, Innovent Biologics, BeiGene, CSPC Pharmaceutical Group, Hansoh Pharmaceutical, China Biologic Products, 3SBIO, Kelun-Biotech, Yinxin Biologics-B, and Rongchang Bio, with the top ten weighted stocks accounting for a total of 69.95% (The individual stocks mentioned in this article are for example purposes only and do not constitute actual investment advice. Funds carry risks, and investment should be approached with caution.) The risk level of the above products is: medium to high (this is the manager's rating; specific sales are subject to the ratings of various distribution agencies). Risk warning: Funds are different from financial instruments with fixed income expectations such as bank savings and bonds. Different types of funds have different risk-return profiles. Investors may share in the profits generated by fund investments, but they may also bear the losses brought about by fund investments. Past performance of funds does not indicate future performance. Investors should understand the risk-return profile of funds and make cautious decisions based on their own investment objectives, time horizons, investment experience, and risk tolerance, and bear the risks themselves. They should not rely on sales practices and promotional materials that do not comply with legal and regulatory requirements